NASDAQ: BTMD · Life Sciences · 2 alerts · CIK 1819253
Share price
$0.9603Close, Nov 16
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All biote Corp. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, biote Corp. reported a net loss of $4.2 million compared to a net income of $29.0 million in the prior year, driven by a decline in total revenue to $132.5 million and increased selling, general, and administrative expenses. The company's cash position decreased significantly to $8.9 million from $24.1 million at year-end 2025, while total stockholders' deficit widened to $57.6 million.
biote Corp. reported third quarter 2026 revenue of $43.3 million, a 9.6% decrease year-over-year, primarily due to a decline in procedure revenue. The company maintained its full-year 2026 outlook, expecting revenue and Adjusted EBITDA to exceed $175 million and $25 million, respectively, despite slower-than-anticipated recovery in underlying demand.
Term
Q3 2026
“While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated. Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”
Bob Peterson, Biote’s interim Chief Executive Officer
“Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a basis for improvement. As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.”
Bob Peterson, Biote’s interim Chief Executive Officer